Suppr超能文献

肠道微生物群在癌症的起始、发展和治疗中的作用

Gut microbiota in cancer initiation, development and therapy.

作者信息

Zhang Ruyi, Zhang Xiang, Lau Harry Cheuk Hay, Yu Jun

机构信息

Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China.

出版信息

Sci China Life Sci. 2024 Dec 30. doi: 10.1007/s11427-024-2831-x.

Abstract

Cancer has long been associated with genetic and environmental factors, but recent studies reveal the important role of gut microbiota in its initiation and progression. Around 13% of cancers are linked to infectious agents, highlighting the need to identify the specific microorganisms involved. Gut microbiota can either promote or inhibit cancer growth by influencing oncogenic signaling pathways and altering immune responses. Dysbiosis can lead to cancer, while certain probiotics and their metabolites may help reestablish micro-ecological balance and improve anti-tumor immune responses. Research into targeted approaches that enhance therapy with probiotics is promising. However, the effects of probiotics in humans are complex and not yet fully understood. Additionally, methods to counteract harmful bacteria are still in development. Early clinical trials also indicate that modifying gut microbiota may help manage side effects of cancer treatments. Ongoing research is crucial to understand better how gut microbiota can be used to improve cancer prevention and treatment outcomes.

摘要

癌症长期以来一直与遗传和环境因素相关,但最近的研究揭示了肠道微生物群在其发生和发展中的重要作用。约13%的癌症与感染因子有关,这凸显了识别其中具体微生物的必要性。肠道微生物群可通过影响致癌信号通路和改变免疫反应来促进或抑制癌症生长。生态失调可导致癌症,而某些益生菌及其代谢产物可能有助于重建微生态平衡并改善抗肿瘤免疫反应。对增强益生菌治疗效果的靶向方法的研究前景广阔。然而,益生菌对人类的影响较为复杂,尚未完全明晰。此外,对抗有害细菌的方法仍在研发中。早期临床试验还表明,调节肠道微生物群可能有助于控制癌症治疗的副作用。持续的研究对于更好地理解如何利用肠道微生物群改善癌症预防和治疗效果至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验